NYLI Mackay证券化收益主动型ETF SECR 深 沪
已收盘 05-08 16:00:00 美东时间
25.59
+0.055
+0.22%
华盛通- 最 高25.60
- 今 开25.59
- 成交量 1991股
- 最 低 25.5452
- 昨 收 25.535
- 总市值 1.61亿
- 52周最高 25.8971
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 23.8874
- 委 比 50.00%
- 总股本 628.81万
- 历史最高 25.8959
- 量 比 1.08
- 振 幅 0.21%
- 历史最低 22.1927
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Commerce Secretary Howard Lutnick And Spirit Chief Executive Dave Davis Agreed That The Budget Carrier Had Run Out Of Options - WSJ
BRIEF-Commerce Secretary Howard Lutnick And Spirit Chief Executive Dave Davis Agreed That The Budget Carrier Had Run Out Of Options - WSJ May 1 (Reuters) - Spirit Aviation Holdings Inc FLYYQ.PK : SECRETARY HOWARD LUTNICK AND SPIRIT CHIEF EXECUTIVE DAVE DAVIS AGREED THAT THE BUDGET CARRIER HAD RUN OU
05-02 09:45
Two Markets In One—Chips And Oil Are Fighting
Intel ripped higher after a Q1 beat, semis stretched their record win streak, Brent held above $104. The market is telling you two different things.
04-25 02:48
WRAPUP 5-Iran shows off its control over strait after collapse of peace talks
WRAPUP 5-Iran shows off its control over strait after collapse of peace talks Adds US boarding supertanker off Sri Lanka in paragraph 4, Iranian source on talks in paragraph 6, Trump post on mines in 7-8 Iranian source: talks only possible if Washington lifts blockade US boards another supertanker i
04-23 13:30
IceCure Reports 4-Year ICESECRET Results, With ProSense Showing Up To 89.4% Recurrence-Free Rates In Kidney Cancer Study
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study populationFull analysis of results to be presented at
03-25 20:39
IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm
IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients. At a median follow-
03-25 20:30
BRIEF-Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board
BRIEF-Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board March 25 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A : APIMEDS PHARMACEUTICALS - APPOINTS YOUNGJIK CHO AS CHAIRMAN OF THE BOARD - SEC FILING APIMEDS PHARMACEUTICALS- ON MAR 20, REMOVES ELONA KOGAN, JAKAP KOO, CAROL O'DONN
03-25 19:20
BRIEF-Lulus Expands Digital Wholesale Footprint With Amazon Storefront And New Partnership With Victoria’S Secret
BRIEF-Lulus Expands Digital Wholesale Footprint With Amazon Storefront And New Partnership With Victoria’S Secret March 17 (Reuters) - Lulu's Fashion Lounge Holdings Inc LVLU.O : LULUS EXPANDS DIGITAL WHOLESALE FOOTPRINT WITH AMAZON STOREFRONT AND NEW PARTNERSHIP WITH VICTORIA’S SECRET Source text:
03-17 18:16
BRIEF-Choice Hotels International Appoints Jeff Lobb As Svp, General Counsel & Secretary
BRIEF-Choice Hotels International Appoints Jeff Lobb As Svp, General Counsel & Secretary March 5 (Reuters) - Choice Hotels International Inc CHH.N : CHOICE HOTELS INTERNATIONAL APPOINTS JEFF LOBB AS SVP, GENERAL COUNSEL & SECRETARY Source text: ID:nPnbH8vBDa Further company coverage: CHH.N (( Reuter
03-05 22:04
BRIEF-Anthropic Says Will Challenge Any Supply Chain Risk Designation In Court
BRIEF-Anthropic Says Will Challenge Any Supply Chain Risk Designation In Court Feb 27 (Reuters) - ANTHROPIC: STATEMENT ON THE COMMENTS FROM SECRETARY OF WAR PETE HEGSETH ANTHROPIC: HAVE TRIED IN GOOD FAITH TO REACH AN AGREEMENT WITH THE DEPARTMENT OF WAR ANTHROPIC: TO THE BEST OF OUR KNOWLEDGE, THES
02-28 09:22
IceCure Medical Completes Five-Year Follow-Up in ICESECRET Kidney Cancer Cryoablation Trial
IceCure Medical Completes Five-Year Follow-Up in ICESECRET Kidney Cancer Cryoablation Trial IceCure Medical Ltd. reported that it has completed the final five-year patient follow-up evaluations in ICESECRET, a prospective, multicenter, single-arm clinical trial of its ProSense cryoablation system fo
02-23 21:31
